Lightweight Ambient Pressure/Temperature O2 Concentrator

轻型常压/常温氧气浓缩器

• 批准号: 6934814
• 负责人: ROBERT B LACOUNT
• 金额: $ 15.3万
• 依托单位: SEPARATION DESIGN GROUP, LLC
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-05-01 至 2006-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6934814
• 关键词: adsorption; atmospheric pressure; bioengineering /biomedical engineering; biomedical equipment development; chronic obstructive pulmonary disease; clinical biomedical equipment; cost effectiveness; evaluation /testing; mathematical model; miniature biomedical equipment; oxygen therapy; portable biomedical equipment; semiconduction

DESCRIPTION (provided by applicant): Chronic Obstructive Pulmonary Disease (COPD) afflicts over 12 million Americans. One million COPD sufferers use Long Term Oxygen Therapy (LTOT) at an annual cost of nearly $2 billion. LTOT is the only medical treatment proven to prolong survival in COPD patients. In order to achieve this survival advantage, oxygen therapy must be prescribed and adhered to for a minimum of 15 hours per day. Lightweight, affordable portable oxygen concentrators are required for these patients if they are to adhere to prescribed therapy and still retain mobility and quality of life. Separation Design Group (SDGroup) is developing an innovative technology that will replace the pressurized mechanical concentrators dominating the market today with a solid state adsoprtion "chip" that electronically produces an enriched flow of oxygen- a truly portable and affordable Lightweight, Ambient Pressure and Temperature Oxygen Concentrator (LAPTOC). During Phase I of the project, we will optimize continuous adsorption technology to produce a minimum of 2 Lpm of 90% oxygen. We will then develop mathematical models of the adsorption chip performance and construct a bench top model. A Phase II prototype is predicted to be entirely safe for air travel, about the size of a portable CD player, weigh less than 3 pounds, operate at under 30 dB for at least 9 hours with optional battery packs, and cost under $1000.

描述（由申请人提供）：慢性阻塞性肺病 (COPD) 困扰着超过 1200 万美国人。 100 万慢性阻塞性肺病 (COPD) 患者使用长期氧疗 (LTOT)，每年花费近 20 亿美元。 LTOT 是唯一被证明可以延长 COPD 患者生存期的医学治疗方法。为了实现这种生存优势，必须每天坚持并坚持至少 15 小时的氧疗。如果这些患者要坚持遵医嘱治疗并仍保持活动能力和生活质量，则需要轻便、价格实惠的便携式制氧机。分离设计集团 (SDGroup) 正在开发一项创新技术，该技术将用固态吸附“芯片”取代当今市场上占主导地位的加压机械浓缩器，该芯片以电子方式产生富氧流，这是一种真正便携式且经济实惠的轻型常压常温氧气浓缩器 (LAPTOC)。在该项目的第一阶段，我们将优化连续吸附技术，以生产至少 2 Lpm 的 90% 氧气。然后，我们将开发吸附芯片性能的数学模型并构建台式模型。第二阶段原型机预计对航空旅行完全安全，其大小与便携式 CD 播放器相当，重量不到 3 磅，使用可选电池组在 30 分贝以下的情况下运行至少 9 小时，成本不到 1000 美元。